- (2025): Li G+, J Thorac Dis 17(4), 2028-2037
- (2015): Benson JL+, Consult Pharm 30(4), 221
Adverse reactions attributed to entire drug class 'Analgesic; opioid'
Please login to view adverse reactions.
Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- (2023): Sherbini AE+, Trends Cardiovasc Med Apr, Online ahead of print [REVIEW]
- (2022): Hahn J+, Front Pharmacol Oct (e-Collection) [REVIEW] (with gabapentinoid co-administration)
- (2023): Hiratsuka Y+, Support Care Cancer 31(12), 6326%
- (2022): Raso J+, Int J Clin Pharm Jan, Online ahead of print (association)
Encephalopathy (includes hepatic encephalopathy)
- (2016): Soleimanpour H+, Hepat Mon 16(4), Epub [REVIEW]
- (2016): Sivanesan E+, Anesth Analg 123(4), 836 [REVIEW]
- (2016): Soleimanpour H+, Hepat Mon 16(4), Epub [REVIEW]
- (2015): Zadori D+, Expert Opin Drug Saf 14(6), 877 [REVIEW]
- (2023): Hiratsuka Y+, Support Care Cancer 31(12), 6325%
- (2021): Tanaka R+, Medicine (Baltimore) 100(44), e27565 (genotype correlation)
Endocrine-related adverse effect / endocrinopathy
- (2021): Medina II WA+, Jul [REVIEW]
Hypogonadism (includes androgen deficiency)
- (2025): Kafel H+, Andrology Feb, Online ahead of print [REVIEW]
- (2025): Boilève A+, Bull Cancer (French) Feb, Online ahead of print [REVIEW]
- (2023): Hiratsuka Y+, Support Care Cancer 31(12), 6325%
- (2022): Alvaro D+, Pain Ther Feb, Online ahead of print [REVIEW]
- (2018): Bhimji SS+, StatPearls Mar, Epub
- (2016): Soleimanpour H+, Hepat Mon 16(4), Epub [REVIEW]
- (2015): Nelson AD+, Therap Adv Gastroenterol 8(4), 206 [REVIEW]
- (2015): Sani H+, Consult Pharm 30(10), 61280%
- (2024): Kang Y+, Int J Mol Sci 25(16), 8845 (pharmacogenomics)
- (2023): Hiratsuka Y+, Support Care Cancer 31(12), 6325%
- (2023): Hiratsuka Y+, Support Care Cancer 31(12), 6325%
- (2023): Lakkad M+, J Cancer Surviv Feb, Online ahead of print (with gabapentinoid)
Adverse effects / adverse reactions
- (2021): Omoto T+, Biol Pharm Bull 44(5), 627-634 [REVIEW]
- (2021): Paul AK+, Pharmaceuticals (Basel) 14(11), 1091 [REVIEW]
- (2014): Carter GT+, Phys Med Rehabil Clin N Am 25(2), 457 [REVIEW]
